Dergiler / Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi / 2021 / Cilt: 24 - Sayı: 2

Duloxetine-induced Restless Legs Syndrome in a Patient with Fibromyalgia Syndrome

Fibromiyalji Sendromlu Bir Hastada Duloksetine Bağlı Huzursuz Bacak Sendromu

Sayfa
183–185
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

To the best of our knowledge, this case report is the first report of RLS symptoms induced by duloxetine during treatment of fibromyalgia syndrome.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Restless legs syndrome (RLS) is a neurological sleep disorder characterized by unpleasant sensations that worsen with resting and sleep, and relieving with moving the limbs.
📊
Temel Bulgular & Veri:Herein we report a 47 year-old woman diagnosed with fibromyalgia syndrome and the dose of 30 mg duloxetine was administered to her.
💡
Sonuç & Katkı:To the best of our knowledge, this case report is the first report of RLS symptoms induced by duloxetine during treatment of fibromyalgia syndrome.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Restless legs syndrome (RLS) is a neurological sleep disorder characterized by unpleasant sensations that worsen with resting and sleep, and relieving with moving the limbs. Herein we report a 47 year-old woman diagnosed with fibromyalgia syndrome and the dose of 30 mg duloxetine was administered to her. Four weeks later from starting duloxetine, uncomfortable sensations appeared in her lower limbs. After the dose of duloxetine had been decreased, her symptoms were alleviated gradually within one week. RLS due to new generation antidepressants is rare and limited with a few case reports in the literature. To the best of our knowledge, this case report is the first report of RLS symptoms induced by duloxetine during treatment of fibromyalgia syndrome.

Abstract

Huzursuz bacak sendromu (HBS), dinlenme ve uyku ile kötüleşen ve ekstremiteleri hareket ettirmekle rahatlayan nahoş hislerle karakterize nörolojik bir uyku bozukluğudur. Burada fibromiyalji sendromu tanısı alan 47 yaşında bir kadın hastaya, 30 mg duloksetin verildi. Duloksetine başladıktan 4 hafta sonra, alt ekstremitelerinde rahatsızlık hissi ortaya çıktı. Duloksetin dozu düşürüldükten sonra semptomları 1 hafta içinde kademeli olarak hafifledi. Yeni nesil antidepresanlara bağlı HBS nadirdir ve literatürde, birkaç olgu sunumu ile sınırlıdır. Bildiğimiz kadarıyla bu olgu sunumu, fibromiyalji sendromunun tedavisi sırasında duloksetinin neden olduğu HBS semptomlarının ilk raporudur.

🔖

Bu Makaleye Atıf Yap

MÜLKOĞLU, C., GENÇ, H. (2021). Duloxetine-induced Restless Legs Syndrome in a Patient with Fibromyalgia Syndrome. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi, Cilt: 24 - Sayı: 2, 183–185. https://ajindex.com/articles/348267

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Chahine LM, Chemali ZN. Restless legs syndrome: a review. CNS Spectr. 2006
  2. [Crossref] [Pubmed] 2. Allen RP, Picchietti DL, Garcia-Borreguero D, et al
  3. International Restless Legs Syndrome Study Group. Restless legs syndrome/ Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-- history, rationale, description, and significance. Sleep Med. 2014
  4. [Crossref] [Pubmed] 3. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011
  5. [Crossref] [Pubmed] 4. Patatanian E, Claborn MK. Drug-induced restless legs syndrome. Ann Pharmacother. 2018
  6. [Crossref] [Pubmed] 5. Allen RP, Barker PB, Wehrl FW, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001
  7. Erratum in: Neurology. 2015
  8. [Crossref] [Pubmed] 6. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001
  9. [Crossref] [Pubmed] 7. Klingelhoefer L, Bhattacharya K, Reichmann H. Restless legs syndrome. Clin Med (Lond). 2016
  10. [Crossref] [Pubmed] [PMC] 8. Lin XW, Zhang JF, Qiu MY, et al. Restless legs syndrome in end stage renal disease patients undergoing hemodialysis. BMC Neurol. 2019
  11. [Crossref] [Pubmed] [PMC] 9. Kolla BP, Mansukhani MP, Bostwick JM. The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. Sleep Med Rev. 2018
  12. [Crossref] [Pubmed] 10. Nikolaou KN, Michopoulos I, Douzenis A, et al. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine. J Clin Psychopharmacol. 2015
  13. [Crossref] [Pubmed] 11. Belli H, Akbudak M, Ural C. Duloxetine-related galactorrhea and restless legs syndrome: a case report. Psychiatr Danub. 2013
  14. [Pubmed] 12. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008
  15. [Crossref] [Pubmed] 13. Härmark L, van Puijenbroek E, van Grootheest K. Intensive monitoring of duloxetine: results of a web-based intensive monitoring study. Eur J Clin Pharmacol. 2013
  16. [Crossref] [Pubmed] [PMC]